Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial GuidanceGlobeNewsWire • 05/10/22
Bioventus Cancels Proposed $415 Million Offering of Senior Notes; Reaffirms Full-Year 2022 Financial GuidanceGlobeNewsWire • 05/03/22
Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee OsteoarthritisGlobeNewsWire • 05/02/22
Bioventus to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022GlobeNewsWire • 04/25/22
Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered LivesGlobeNewsWire • 04/08/22
Bioventus Announces Inducement Equity to SVP Chief Financial Officer Mark SingletonGlobeNewsWire • 04/05/22
Bioventus Inc. (BVS) CEO Ken Reali on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/10/22
Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial GuidanceGlobeNewsWire • 03/10/22
Bioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022GlobeNewsWire • 02/22/22
Bioventus Inc. (BVS) CEO Ken Reali on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/14/21
Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial GuidanceGlobeNewsWire • 11/09/21